clinical trial · NCT06454188
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
CARE ARTHRITIS LTD.·phase4·recruiting·n = 100
Psoriatic ArthritisSpondyloarthritis, AxialUpadacitinib 15 MG [Rinvoq]Placebo
brief summary
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
started
Dec 3, 2024
primary completion
Sep 1, 2028
completion
Oct 1, 2028
last updated
Apr 3, 2026
official title
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol